Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Chronic hepatitis C infection for at least 6 months duration~* Hepatitis C genotype 1a or 1b~* Patients must have discontinued prior hepatitis C treatment at least 12 weeks prior to enrollment in this study~* Patient showed a previous null response to therapy as defined by \< 2 log10 IU/mL decrease in viral titer after at least 12 weeks of treatment with PEG-IFN/RBV~Exclusion Criteria:~* Hepatitis C infection with a genotype other than genotype 1a or 1b~* Body mass index \<18 or \>/=36~* Hepatitis A, hepatitis B, or HIV infection~* Herbal remedies \</=1 month prior to the first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm A (Type: EXPERIMENTAL): 24 weeks of therapy with mericitabine 1000 mg twice a day (BID), boceprevir 800 mg three times daily (TID), Pegasys 180 microgram/week, and Copegus 1000/1200 mg/day (total treatment duration of 24 weeks), followed by a 24-week treatment-free follow-up period.
- Treatment Arm B (Type: EXPERIMENTAL): 24 weeks of therapy with mericitabine + boceprevir + Pegasys/Copegus followed by 24 weeks of therapy with boceprevir + Pegasys/Copegus (triple) (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
- Treatment Arm C (Control) (Type: ACTIVE_COMPARATOR): 4 weeks of therapy with mericitabine placebo, boceprevir placebo + Pegasys/Copegus, then 20 weeks of therapy with mericitabine placebo + boceprevir + Pegasys/Copegus, then 24 weeks of therapy with boceprevir + Pegasys/Copegus (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).